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Introduction. Sulfonamides were the first chemotherapeutic drugs with wide 
spectrum of activity that have application in practical medicine. Since discovery in 
1935 of antimicrobial properties of sulfanilamide 6 000 sulfa substances were 
synthesized and studied, 40of these compounds are used in medical practice. 
Early efforts in the development of anti-infective drugs. For much of 
history, infectious diseases were the leading cause of death in most of the world. The 
widespread use of vaccines and implementation of public health measures, such as 
building reliable sewer systems and chlorinating water to assure safe supplies for 
drinking, were of great benefit in decreasing the impact of infectious diseases in the 
industrialized world. However, even with these measures, pharmaceutical treatments 
for infectious diseases were needed. The first of these was arsphenamine, which was 
developed in 1910 by the German medical scientist Paul Ehrlich, who is a founder of 
modern chemotherapy, for the treatment of syphilis. Arsphenamine was the 606th 
chemical studied by Ehrlich in his quest for an antisyphilitic drug. Its efficacy was 
first demonstrated in mice with syphilis and then in humans. Arsphenamine was 
marketed with the trade name of Salvarsan and was used to treat syphilis until the 
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1940s, when it was replaced by penicillin. Ehrlich referred to his invention 
aschemotherapy, which is the use of a specific chemical to combat a specific 
infectious organism. Arsphenamine was important not only because it was the first 
synthetic compound to kill a specific invading microorganism but also because of the 
approach Ehrlich used to find it. In essence, he synthesized a large number of 
compounds and screened each one to find a chemical that would be effective. 
Screening for efficacy became one of the most important means used by the 
pharmaceutical industry to develop new drugs. 
The discovery of sulfanilamide. The next great advance in the development of 
drugs for treatment of infections came in the 1930s, when it was shown that 
certain azo dyes, which contained sulfonamide groups, were effective in 
treating streptococcal infections in mice. One of the dyes, known as Prontosil, was 
later found to be metabolized in the patient to sulfanilamide, which was the active 
antibacterial molecule. In 1933Prontosil was given to the first patient, an infant with a 
systemic staphylococcal infection. The infant underwent a dramatic cure [1]. 
Daniel Bovet's team at the Pasteur Institute in Paris discovered that 
sulfanilamide (4-aminobenzenesulfonamide), was itself active both in vitro and in 
vivo. Intestinal enzymes in the human body convert Prontosil into sulfanilamide, the 
active molecule; there were no enzymes in the bacterial cultures upon which 
Prontosilhad been tested, which is why Prontosil was inactive in vitro. One advantage 
of sulfanilamide over Prontosil was that the skin of patients was not turned red. 
Moreover, sulfanilamide was much cheaper than Prontosil. It had first been prepared 
in Vienna in 1908 by Paul Gelmo, in the course of his PhD researches. It was 
patented in 1909, so that the patent had expired by the time that Bovet's team made 
their discovery. Bovet was later to receive the 1957 Nobel Prize for Physiology or 
Medicine [2, 3]. 
In subsequent years many derivatives of sulfonamides, or sulfa drugs, were 
synthesized and tested for antibacterial and other activities. 
Interesting historical facts about sulfanilamide application. The 69-year-old 
British Prime Minister, Winston Churchill, had two bouts of pneumonia in 1943, the 
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first one in February. At the Teheran conference, concerned with finalising strategy 
for the war against Nazi Germany held between November 28th and December 1st 
that year, he met the President of the United States, Franklin Roosevelt, and Joseph 
Stalin, Leader of the Soviet Union.  
After this meeting, he went to General Eisenhower's villa near Carthage but en 
route spent an hour sitting on an airfield in a cold wind. He slept for the rest of the 
day, December 11th, then complained of a sore throat. Next day, his temperature rose 
to 101°F. A portable X-ray machine revealed a shadow on the lung; it was pneumonia 
again. Immediately Churchill was given the new antibiotic made by the British firm 
of May and Baker; the tablets were simply known as 'M&B'. Churchill had a mild 
heart attack on December 15th, but his condition improved and he convalesced by 
having Pride and Prejudice read to him. He compromised on his habits by agreeing 
to drink only weak whisky and soda and not to smoke at all. No cigars. He is quoted 
as saying: "Dear Nurse, pray remember that man cannot live by M & B alone." His 
doctors, Lord Moran and Dr Bedford, were also M & B. 
Subsequently Churchill issued a saying "Excellent nurses and the highest 
medical authorities in the Mediterranean arrived from all quarters as if by magic. 
This admirable M & B, from which I did not suffer any inconvenience, was used at 
the earliest moment and after a week's fever the intruders were repulsed." 
At this distance of time, it is not clear whether the drug used was M&B 693, 
sulfapyridine, or else M&B 760, sulfathiazole, though it is more likely to have been 
the former. And if it had not been for a German scientist, it is quite possible that this 
drug might not have been available [4]. 
The discovery of Sulfanilamide greatly affected the mortality rate during World 
War II. American soldiers were taught to immediately sprinkle sulfa powder on any 
open wound to prevent infection. Every soldier was issued a first aid pouch that was 
designed to be attached to the soldier’s waist belt. The first aid pouch contained a 
package of sulfa powder and a bandage to dress the wound. One of the main 
components carried by a combat medic during World War II was sulfa powder and 
sulfa tablets. 
 Synthesis of sulfanilamide. 
four steps (Fig.1). Aniline is first acetylated to protect the easily oxidised amine 
group; sulfonated using chlorosulfonic acid; ammonia is added to generate the 
sulfonamide group; and finally boiling with dilute HCl removes the protecting acetyl 
group, which is more easily hydrolysed than the sulfonamide group
 
Mechanism of sulfanilamide action. 
was discovered in 1940 by Donald Woods, researching in Oxford. He found 
that para-aminobenzoic acid 
effects, and noted that these two molecules had very similar 
PABA is used by bacteria to make dihydrofolic acid, which is then used to make 
other molecules including the purine bases necessary to construct DNA, so it is 
absolutely vital to the bacteria. One stage of the synthesis of dihydrofolic acid is 
catalysed by the enzyme dihydropteroatesynthetase; sulfanilamide fits the active site 
of this enzyme, and blocks the site to PABA, so that the bacterium cannot multiply 
and grow. Thus the immune system has the opportunity to clear up the infection
Sulfanilamide can readily be made from aniline in 
Fig. 1. Sulfanilamide synthesis 
The mechanism of sulfanilamide's action 
– PABA (Fig. 2) stopped sulfanilamide's antibacterial 
structures.
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 [8,9]. 
  
Fig. 2. Structure of sulfanilamide and 
Unlike bacteria, humans do not make dihydrofolic acid. They take in folic acid 
from their diet as a vitamin (from green vegetables for example), so we 
any dihydropteroatesynthetase, and that's why sulfanilamide is safe for humans.
Some inhibitors prevent, or block, enzymatic action by reacting with groups at 
the active site. The nerve gas diisopropylfluorophosphate, for example, reacts with 
the serine at the active site of acetylcholinesterase to form a covalent bond. The 
nerve-gas molecule involved in bond formation prevents the active site from binding 
the substrate, acetylcholine, thereby blocking catalysis and nerve action. Iodoacetic 
acid similarly blocks a key enzyme in muscle action by forming a bulky group on the 
amino acid cysteine, which is found at the enzyme’s active site. This process is
irreversible inhibition.  
Some inhibitors modify amino acids other than those at the acti
in loss of enzymatic activity. The inhibitor causes changes in the shape of the active 
site. Some amino acids other than those at the active site, however, can be modified 
without affecting the structure of the active site; in these case
not affected. Such chemical changes parallel natural mutations. Inherited diseases 
frequently result from a change in an amino acid at the active site of an enzyme, thus 
making the enzyme defective. In some cases, an amino acid chang
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p-aminobenzoic acid 
p-aminobenzoic acid
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don't have 
 
 called 
ve site, resulting 
s, enzymatic action is 
e alters the shape 
 of the active site to the extent that it can no longer react; such diseases are usually 
fatal. In others, however, a partially defective enzyme is formed, and an individual 
may be very sick but able to live
Modern derivatives of sulfanilamide. 
50 years ago, since some bacteria have acquired immunity to them; there is also the 
possibility of liver damage and of allergic reactions, such as Stevens
syndrome. However, other molecules which retain their activity for longer have been 
synthesized; they tend to be used to treat infections of the urinary tract and in certain 
sexually transmitted infections like 
A mixture of sulfamethoxazole and trimethoprim, kn
(Biseptol), has been used to treat a variety of infections, though this is now more 
restricted. It has been recommended for HIV
situations. It can be an effective "broad spectrum" antibiotic aga
illnesses because sulfamethoxazole
successive steps in the biosynthesis of tetrahydrofolic acid
each molecule can be used in the drug. It's a kind of double
concerns about side-effects mean that it sees limited use
Sulfamethoxazole
Fig.
                                  
 [10]. 
Sulfa drugs are not used as much now as 
Chlamydia. 
own as Co
-exposed infants and children in certain 
 (Fig. 3) and trimethoprim
 (Fig.
-
 [11]. 
 
 Sulfadoxine
 3. Structure of the sulfadrug derivatives
 
Fig. 4. Structure of trimethoprim 
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 Fig. 5. Blocking of 
 
Sulfa drugs were first used in malaria treatment in the 1930s, but were 
superseded by other agents like chloroquine, which in its turn has become less 
effective. A combination of sulfadoxine
been used to treat chloroquine
similarly targets the two enzymes in the synthesis of tetrahydrofolic acid. Side effects 
means that it is only employed for severe cases, and its use is now discon
UK [12]. 
Despite this, sulfonamides were the first widely used and successful examples of 
chemotherapy, using synthetic chemicals to fight diseases. They were also the first 
example of the use of a competitive enzyme inhibitor as a drug.
Sulfanilamide is one of the first representatives of the antimicrobial drugs. 
Despite great advances in the production of antibiotics,
among the most commonly used antibacterial agents.
The mechanism of antibacterial action of sulfonamides is inhibition the  
formation of folic and di
synthesis of purines and pyrimidines. Blocking of this metabolic chain leads to 
stopping of growth and reproduction, i.e. a bacteriostatic effect.
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В статье описан метод синтеза сульфаниламида (стрептоцида), 
приведены исторические факты, связанные с открытием и применением 
сульфаниламидных препаратов. Рассматриваются современные и 
перспективные производные сульфаниламидов.  
Ключевые слова: сульфаниламид, пара-аминобензойная кислота, 
дигидрофолиевая кислота,  микроорганизмы, бактериостатический эффект, 
сульфаметоксазол, триметоприм. 
 
ОДЕРЖАННЯ СУЛЬФАНІЛАМІДНИХ ПРЕПАРАТІВ ТА ЇХ 
ЗАСТОСУВАННЯ 
 
 Ю. І. ГАЛУЗІНСЬКА, Д. В. СЄДЮКО, І. І. ГЕРАЩЕНКО 
Національний авіаційний університет, м. Київ 
 
У статті описано метод синтезу сульфаніламіду (стрептоциду), 
наведено історичні факти, пов’язані з відкриттям й застосуванням 
сульфаніламідних препаратів.  Розглянуто сучасні та перспективні похідні 
сульфаніламідів. 
Ключові слова: сульфаніламід, пара-амінобензойна кислота, 
дигідрофолієва кислота, мікроорганізми, бактеріостатичний ефект, 
сульфаметоксазол, триметоприм.  
